Scientech Research LLC Buys New Shares in Guardant Health, Inc. (NASDAQ:GH)

Scientech Research LLC bought a new stake in shares of Guardant Health, Inc. (NASDAQ:GH) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 59,023 shares of the company’s stock, valued at approximately $1,705,000.

Other large investors have also recently bought and sold shares of the company. Manchester Capital Management LLC bought a new stake in Guardant Health in the 1st quarter valued at $57,000. Canton Hathaway LLC bought a new stake in Guardant Health in the 2nd quarter valued at $59,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in Guardant Health in the 2nd quarter valued at $71,000. EntryPoint Capital LLC bought a new stake in Guardant Health in the 1st quarter valued at $75,000. Finally, Byrne Asset Management LLC bought a new stake in Guardant Health in the 2nd quarter valued at $77,000. 92.60% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on GH. TD Cowen boosted their price target on shares of Guardant Health from $41.00 to $42.00 and gave the company a “buy” rating in a report on Thursday, August 8th. Bank of America boosted their price target on shares of Guardant Health from $28.00 to $40.00 and gave the company a “buy” rating in a report on Thursday, July 18th. JPMorgan Chase & Co. upped their target price on shares of Guardant Health from $45.00 to $48.00 and gave the stock an “overweight” rating in a report on Thursday, August 8th. BTIG Research upped their target price on shares of Guardant Health from $45.00 to $50.00 and gave the stock a “buy” rating in a report on Tuesday, July 30th. Finally, UBS Group upped their target price on shares of Guardant Health from $32.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, August 21st. One equities research analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, Guardant Health presently has an average rating of “Moderate Buy” and an average target price of $39.31.

Guardant Health Stock Up 1.9 %

Shares of NASDAQ GH opened at $22.73 on Friday. The firm’s 50-day simple moving average is $28.08 and its 200 day simple moving average is $25.11. The company has a market cap of $2.80 billion, a price-to-earnings ratio of -5.80 and a beta of 1.11. The company has a quick ratio of 6.07, a current ratio of 6.40 and a debt-to-equity ratio of 16.70. Guardant Health, Inc. has a 12-month low of $15.81 and a 12-month high of $37.04.

Guardant Health (NASDAQ:GH) last issued its quarterly earnings results on Wednesday, August 7th. The company reported ($0.84) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.74) by ($0.10). The company had revenue of $177.24 million for the quarter, compared to analyst estimates of $162.59 million. Guardant Health had a negative return on equity of 418.21% and a negative net margin of 76.23%. The firm’s quarterly revenue was up 29.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.67) EPS. On average, research analysts expect that Guardant Health, Inc. will post -3.31 earnings per share for the current fiscal year.

Guardant Health Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.